1. Home
  2. WIT vs INSM Comparison

WIT vs INSM Comparison

Compare WIT & INSM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Wipro Limited

WIT

Wipro Limited

HOLD

Current Price

$2.31

Market Cap

23.3B

Sector

Technology

ML Signal

HOLD

Logo Insmed Incorporated

INSM

Insmed Incorporated

HOLD

Current Price

$140.44

Market Cap

35.2B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
WIT
INSM
Founded
1945
1988
Country
India
United States
Employees
242021
N/A
Industry
EDP Services
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
23.3B
35.2B
IPO Year
2000
2000

Fundamental Metrics

Financial Performance
Metric
WIT
INSM
Price
$2.31
$140.44
Analyst Decision
Strong Buy
Analyst Count
0
23
Target Price
N/A
$188.73
AVG Volume (30 Days)
11.8M
2.1M
Earning Date
01-01-0001
05-21-2026
Dividend Yield
4.93%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$6.75
$168.46
Revenue Next Year
$6.67
$65.97
P/E Ratio
$16.59
N/A
Revenue Growth
N/A
N/A
52 Week Low
$2.11
$60.40
52 Week High
$3.24
$212.75

Technical Indicators

Market Signals
Indicator
WIT
INSM
Relative Strength Index (RSI) 46.75 34.85
Support Level N/A $139.81
Resistance Level $2.86 $167.01
Average True Range (ATR) 0.07 6.70
MACD 0.02 -0.57
Stochastic Oscillator 81.67 0.58

Price Performance

Historical Comparison
WIT
INSM

About WIT Wipro Limited

Wipro is a multinational IT services provider based in Bengaluru, India. The company pivoted into the IT space in the 1980s and grew into one of the largest Indian IT consulting companies during the dot-com boom. Nowadays, Wipro leverages its offshore outsourcing model to derive a significant portion of its revenue from North America and Europe.

About INSM Insmed Incorporated

Insmed Inc is a biopharmaceutical company. Its commercial portfolio and clinical pipeline are organized around three therapeutic areas: Respiratory, Immunology and Inflammation, and Neuro and Other Rare. The company's two commercial products, Arikayce and Brinsupri, are both part of the Respiratory therapeutic area. The firm's clinical-stage programs are TPIP, INS1148, brensocatib, and INS1201, focusing on different therapeutic areas. Additionally, Insmed's pre-clinical research programs encompass various technologies and modalities, including gene therapy, AI-driven protein engineering, protein manufacturing, RNA end-joining, and synthetic rescue. Geographically, the company generates maximum revenue from the United States from the sale of its commercial products.

Share on Social Networks: